Table 4 Clinical characteristics and prognosis in the present study compared with previous studies in some developed countries
From: A real-world study on diagnosis and prognosis of light-chain cardiac amyloidosis in Southern China
Present study (n = 170) | Pinney et al. [5] (n = 36) | Sidana [6] (n = 405) | Quarta et al. [14] (n = 80) | |
|---|---|---|---|---|
Country | Changsha, China | London, UK | Rochester, USA | Boston, USA |
Age at diagnosis (years) | 60.81 (± 10.46) | 63.0 (56.6–65.8) | 65 (58–73) | 62 (± 10) |
Male (%) | 70.59% | 69% | 64% | 66% |
Major manifestation leading diagnosis (%) | HF (72.3%) | HF (80.5%) | NA | HF (66%) |
Pacemaker | 8.2% | 5.5% | NA | NA |
Atrial fibrillation | 17.7% | 11% | NA | 8% |
NYHA III or IV (%) | 76.47% | 60% | NA | 29% |
eGFR, mL/(min × 1.73m2) | 60.6 (± 31.4) | 64 (48–87) | 62 (46–77) | 64 (± 27) |
NT-proBNP, pg/mL | 6139.4 (2957.7–11,754.0) | 714.0 (427.5–1573.0) pmol/L | 4484 (1846–10 243) | 3085 (1314–11,260) |
IVS, mm | 14.1 (± 3.6) | 15 (± 2) | NA | 15 (± 2) |
LVPW, mm | 13.6 (± 3.3) | 15 (± 2) | NA | 14 (± 2) |
LVEF, (%) | 52.9 (± 10.0) | 47.8 (± 12.6) | NA | 56 (± 14) |
QTc, ms | 471.6 (± 36.7) | 596.6 (± 745.0) | NA | NA |
Low voltage | 57.1% | 27% | NA | 45% |
Median survival (month) | 8.0 | 10.4 | 16 | 12 |